Sedastop vet.

1 x 10 ml

Liquid for injection, solution

Active substance

Atipamezol (Atipamezole hydrochloride) : 5 mg/ml

ATC code

QV03AB90 Atipamezole

QV03AB Antidotes

QV03A All other therapeutic products

QV03 All other therapeutic products

QV Various

Species

Dogs and cats

Indications

Atipamezole hydrochloride is indicated for reversal of the sedative effects and cardiovascular effects after use of alpha-2- agonists like medetomidine and dexmedetomidine in dogs and cats.

Dose to be administered and administration route

Intramuscular use.

Atipamezole hydrochloride is administered 15-60 min after medetomidine or dexmedetomidine hydrochloride administration.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Dogs: The intramuscular atipamezole hydrochloride dose [in µg] is five times that of the previous medetomidine hydrochloride dose or ten times that of the dexmedetomidine hydrochloride dose. Due to the 5-fold higher concentration of the active ingredient (atipamezole hydrochloride) in this veterinary medicinal product compared to that of preparations containing 1 mg medetomidine hydrochloride per ml and the 10-fold higher concentration compared to that of preparations containing 0.5 mg dexmedetomidine hydrochloride, an equal volume of each preparation is required.

Dosage example Dogs:

Medetomidine 1 mg/ml solution for injection dosage	Narcostop 5 mg/ml solution for injection for dogs dosage
0.04 ml/kg body weight (bw),	0.04 ml/kg bw,
i.e. 40 µg/kg bw	i.e. 200 µg/kg bw
Dexmedetomidine 0.5 mg/ml solution for injection dosage	Narcostop 5 mg/ml solution for injection for dogs dosage
0.04 ml/kg body weight (bw), i.e. 20 µg/kg bw	0.04 ml/kg bw, i.e. 200 µg/kg bw

Cats: The intramuscular atipamezole hydrochloride dose [in µg] is two-and-a-half times that of the previous medetomidine hydrochloride dose or five times that of the dexmedetomidine hydrochloride dose. Due to the 5-fold higher concentration of the active ingredient (atipamezole hydrochloride) in this veterinary medicinal product compared to that of preparations containing 1 mg medetomidine hydrochloride per ml and the 10-fold higher concentration compared to that of preparations containing 0.5 mg dexmedetomidine hydrochloride, half the volume of the veterinary medicinal product to that of the previously administered medetomidine or dexmedetomidine should be given.

Dosage example Cats:

Medetomidine 1 mg/ml solution for injection dosage	Narcostop 5 mg/ml solution for injection for cats dosage
0.08 ml/kg body weight (bw), i.e. 80 µg/kg bw	0.04 ml/kg bw, i.e. 200 µg/kg bw
Dexmedetomidine 0.5 mg/ml solution for injection dosage	Narcostop 5 mg/ml solution for injection for cats dosage
0.08 ml/kg body weight (bw), i.e. 40 µg/kg bw	0.04 ml/kg bw, i.e. 200 µg/kg bw

The recovery time is shortened to approximately 5 minutes. The animal becomes mobile after approximately 10 minutes after administration of the veterinary medicinal product.

Adverse reactions

Dogs and cats:

Rare

(1 to 10 animals / 10,000 animals treated):

Hyperactivity, Vocalisation^a, Inappropriate urination, Inappropriate defecation

Tachycardia

Increased salivation, Vomiting

Muscle tremor

Increased respiratory rate

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Hypotension^b

Sedation^c, Recovery prolonged^d

Hypothermia^e

^a Atypical.

^b Transient effect that has been observed during the first 10 minutes post-injection of atipamezole hydrochloride. ^c Recurrence. ^d The recovery time may not be shortened after administration of atipamezole.

^e Only in cats, when using low doses to partially reverse the effects of medetomidine or dexmedetomidine. Should be guarded against, even when aroused from sedation.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.